Newly or maybe pregnant, or hoping for good news soon? If you are also currently taking Cimzia, consider taking part in the CHERISH Clinical Research Study!
Pregnancy can affect symptoms and possibly response to treatment, and data regarding treatment with biologics during pregnancy is limited, which leaves women and physicians without objective scientific evidence regarding ideal dosing during pregnancy. This study will track participants through their pregnancy, and measure changes in blood plasma levels of Cimzia during pregnancy, and after delivery.
You may be eligible to participate in this study if you are 18 years of age or older, and you:
- Have been pregnant for 10 weeks or less at the time of enrolling in the study
- Are currently being treated with Cimzia for a chronic inflammatory condition and have been on a stable maintenance dose for at least three months
- Are likely to continue receiving Cimzia throughout your pregnancy, and for at least three months after your delivery
Learn More about this study and enroll here https://thecherishstudy.com/us/en/research-studies or by calling (877) 302-2822 toll-free.
This study is listed on Clinical Trials: A Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol) – Full Text View – ClinicalTrials.gov
The study is sponsored by UCB BioPharma, SPRL.